Västra Hamnen Corp. Finance
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
CombiGene: Advancements according to plan
- New agreement with Spark Therapeutics regarding CG01
- Activities advances the COZY programme
- We keep our fair value of SEK 12.19 per share
During CombiGene's Q2, the most significant event was the licensing agreement with Spark Therapeutics, which formally returns CG01 to CombiGene. The company will gain access to study data, while Spark will receive single-digit royalties on an approved product. Progress has also been made within the COZY program, including a study confirming that the target protein is expressed in human peripheral neuronal tissue. Financially, the company reported a cash flow of MSEK -17.8 for Q2 and had cash holdings of MSEK 83.5 at the end of the period. We maintain our fair value of SEK 12.19 per share.
The full report is available here.
| Datum | 2024-08-29, kl 14:00 |
| Källa | MFN |